HC Wainwright Forecasts Aktis Oncology Q1 Earnings

Aktis Oncology (NASDAQ:AKTS) – Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Aktis Oncology in a report issued on Tuesday, March 31st. HC Wainwright analyst R. Burns expects that the technology company will post earnings per share of ($0.54) for the quarter. HC Wainwright currently has a “Buy” rating and a $33.00 target price on the stock. The consensus estimate for Aktis Oncology’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q2 2027 earnings at ($0.57) EPS, Q3 2027 earnings at ($0.60) EPS and Q4 2027 earnings at ($0.63) EPS.

Other analysts also recently issued reports about the company. Leerink Partners assumed coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 target price on the stock. TD Cowen started coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating for the company. Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Bank of America assumed coverage on shares of Aktis Oncology in a research note on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 price objective on the stock. Finally, JPMorgan Chase & Co. initiated coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 target price for the company. Five equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Aktis Oncology has a consensus rating of “Buy” and an average target price of $32.00.

Aktis Oncology Stock Performance

AKTS opened at $17.07 on Wednesday. Aktis Oncology has a 1-year low of $14.72 and a 1-year high of $29.16. The stock has a 50 day moving average price of $19.13.

Insider Activity at Aktis Oncology

In related news, major shareholder Bioventures 2018 L.P. Mpm acquired 1,112,777 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $20,029,986.00. Following the transaction, the insider owned 10,260,064 shares in the company, valued at $184,681,152. This trade represents a 12.17% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ansbert Gadicke bought 1,112,777 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was purchased at an average cost of $18.00 per share, with a total value of $20,029,986.00. Following the purchase, the insider directly owned 10,260,064 shares in the company, valued at $184,681,152. The trade was a 12.17% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 6,117,776 shares of company stock valued at $110,119,968 in the last ninety days. 3.30% of the stock is owned by insiders.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.